-
Je něco špatně v tomto záznamu ?
Caveolin-1 as a potential high-risk prostate cancer biomarker
J. Gumulec, J. Sochor, M. Hlavna, M. Sztalmachova, S. Krizkova, P. Babula, R. Hrabec, A. Rovny, V. Adam, T. Eckschlager, R. Kizek, M. Masarik
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS10200
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Free Medical Journals
od 2006 do Před 1 rokem
ProQuest Central
od 2012-01-01
Health & Medicine (ProQuest)
od 2012-01-01
PubMed
22159333
DOI
10.3892/or.2011.1587
Knihovny.cz E-zdroje
- MeSH
- antioxidancia metabolismus MeSH
- bifenylové sloučeniny krev MeSH
- chromany (dihydrobenzopyrany) krev metabolismus MeSH
- glutathion krev MeSH
- kaveolin 1 krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery krev MeSH
- nádory prostaty krev MeSH
- oxidační stres MeSH
- peroxidy krev MeSH
- pikráty krev MeSH
- senioři MeSH
- sloučeniny chromu krev MeSH
- volné radikály krev MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12034835
- 003
- CZ-PrNML
- 005
- 20141105150135.0
- 007
- ta
- 008
- 121023s2012 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/or.2011.1587 $2 doi
- 035 __
- $a (PubMed)22159333
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Gumulec, Jaromír, $d 1963- $7 xx0054104 $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, and Department of Urology, St. Anne's University Hospital Brno, CZ-625 00 Brno, Czech Republic.
- 245 10
- $a Caveolin-1 as a potential high-risk prostate cancer biomarker / $c J. Gumulec, J. Sochor, M. Hlavna, M. Sztalmachova, S. Krizkova, P. Babula, R. Hrabec, A. Rovny, V. Adam, T. Eckschlager, R. Kizek, M. Masarik
- 520 9_
- $a Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antioxidancia $x metabolismus $7 D000975
- 650 _2
- $a bifenylové sloučeniny $x krev $7 D001713
- 650 _2
- $a kaveolin 1 $x krev $7 D051242
- 650 _2
- $a chromany (dihydrobenzopyrany) $x krev $x metabolismus $7 D002839
- 650 _2
- $a sloučeniny chromu $x krev $7 D017608
- 650 _2
- $a volné radikály $x krev $7 D005609
- 650 _2
- $a glutathion $x krev $7 D005978
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a oxidační stres $7 D018384
- 650 _2
- $a peroxidy $x krev $7 D010545
- 650 _2
- $a pikráty $x krev $7 D010851
- 650 _2
- $a nádory prostaty $x krev $7 D011471
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1#
- $a Sochor, J. $7 _AN063450
- 700 1#
- $a Hlavna, Marian. $7 _AN049680
- 700 1_
- $a Sztalmachová, Markéta $7 xx0146032
- 700 1_
- $a Křížková, Soňa, $d 1981- $7 xx0105812
- 700 1_
- $a Babula, Petr, $d 1979- $7 xx0074947
- 700 1_
- $a Hrabec, Roman
- 700 1_
- $a Rovný, Arne, $d -2012 $7 xx0106969
- 700 1_
- $a Adam, Vojtěch, $d 1982- $7 xx0064599
- 700 1_
- $a Eckschlager, Tomáš, $d 1956- $7 jn20000400613
- 700 1_
- $a Kizek, René, $d 1972- $7 jn20001005291
- 700 1_
- $a Masařík, Michal $7 xx0104244
- 773 0_
- $w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 27, č. 3 (2012), s. 831-841
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22159333 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20121023 $b ABA008
- 991 __
- $a 20141105150143 $b ABA008
- 999 __
- $a ok $b bmc $g 956845 $s 792332
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 27 $c 3 $d 831-841 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
- GRA __
- $a NS10200 $p MZ0
- LZP __
- $a Pubmed-20121023